Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-17T12:43:12.170Z Has data issue: false hasContentIssue false

4277 Functional consequences of the juvenile idiopathic arthritis risk variant at 1q24.3

Published online by Cambridge University Press:  29 July 2020

Halima Moncrieffe
Affiliation:
Cincinnati Children’s Hospital
Katelyn Dunn
Affiliation:
Cincinnati Children’s Hospital
Yongbo Huang
Affiliation:
Cincinnati Children’s Hospital
Xiaoting Chen
Affiliation:
Cincinnati Children’s Hospital
Carl D. Langefeld
Affiliation:
Wake Forest School of Medicine
Matthew T. Weirauch
Affiliation:
Cincinnati Children’s Hospital
John B. Harley
Affiliation:
Cincinnati Children’s Hospital
Leah C. Kottyan
Affiliation:
Cincinnati Children’s Hospital
Susan D. Thompson
Affiliation:
Cincinnati Children’s Hospital
Juvenile Arthritis Consortium for the Immunochip
Affiliation:
Cincinnati Children’s Hospital
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatologic disease childhood and a cause of pain and potential disability. JIA has a strong genetic component and no known cure. The goal of this study is to evaluate allele-dependent effects of a novel JIA risk variant at 1q24.3. METHODS/STUDY POPULATION: JIA patients meeting criteria for the two most common disease subtypes (oligoarticular and RF neg polyarthritis) were genotyped using the Immunochip, an Illumina array with dense coverage of the HLA region and 186 other loci previously reported in autoimmune diseases. Phase I association findings (Hinks, 2013) and Phase II analysis (unpublished) of an expanded cohort (4,271 JIA and 14,390 controls) identified new risk loci, including rs78037977 at 1q24.3. We prioritized rs78037977 and predicted possible impacted mechanisms based on Bayesian predictions of attributable risk, the surrounding chromatin landscape, and transcription factor binding data. A luciferase reporter assay was used to assess allele-dependent enhancer activity. RESULTS/ANTICIPATED RESULTS: rs78037977 is located between FASLG and TNFSF18 at chromosome 1q24.3 is associated with JIA (p = 6.3x10−09), and explains 94% of the posterior probability at this locus; no other SNPs in linkage disequilibrium (r2>0.6). The chromatin landscape around rs78037977 contains H3K4Me1 and H3K27Ac marks, which are indicative of enhancer activity. Further, >160 transcription factors have chromatin immunoprecipitation followed by sequencing (ChIP-seq) peaks overlapping rs78037977 in various cellular contexts. In luciferase reporter assays, the region around rs78037977 containing the reference A allele had ~2-fold increased enhancer activity compared to the non-reference allele. DISCUSSION/SIGNIFICANCE OF IMPACT: This work provides in vitro evidence to support allele-dependent enhancer activity of a novel JIA-risk variant at 1q24.3. Our ongoing work investigates the effect of the DNA-containing region of rs78037977 on gene expression and differential transcription factor binding at rs78037977.

Type
Mechanistic Basic to Clinical
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Association for Clinical and Translational Science 2020